Immunotherapy
with cytokines or cytokine-activated effector cells is a promising therapeutic approach, which has not been extensively evaluated in patients with head and neck cancer (HNC) progress. An urgent need exists in head and neck oncology for effective adjuvant therapy, and immunotherapy with immune effector cells should be considered as a feasible therapeutic modality in the adjuvant setting in HNC.
Head and neck cancer (HNC) represents about 6% of all new cases of cancer in the United States according to Cancer Statistics, 1994.1) Despite attempts at prevention of tobacco use and possibilities for earlier detection, the majority of patients still present with relatively advanced locoregional disease. Survival of patients with HNC has not improved in the last 30 years (50-60% five-year survival), and surgical treatment of HNC results in considerable functional and cosmetic morbidity. Standard therapy has consisted of surgery and/or radiotherapy. A better understanding of the biology of HNC is necessary in order to begin developing new, more effective approaches to therapy in order to improve both survival and quality of life of patients with this type of cancer. In spite of highly sophisticated surgical procedures in use today, the high frequency of recurrence has NA-NK cells. Also, the 51Cr-labeled A-NK cells accumulated inside the spheroids better than NA-NK cells or CTL (Table 2 ). These findings suggest that A-NK cells preferentially have the ability to enter into multicellular tissue-like formations. We have also shown that A-NK cells are better able to lyse SCCHN spheroids than NA-NK cells (Fig.1) .
To explain the excellent ability of the A-NK cell subset to enter solid tissues, we postulated that their enzymatic activities may play an essential role in this function. Indeed, we have preliminary evidence that A-NK cells can produce collagenase-like activity, urokinase and tissue-plasminogen activator as well as degrade gelatin. Also, bestatin, an inhibitor of ectoaminopeptidases, was able to block entry of A-NK cells into PCI-50 spheroids (data not shown). These observations support our hypothesis that A-NK Following infection, the T cells have been cultured in the presence of 300 IU/ml of interleukin 2 (IL2) and 300 U/ml of IL4 for over 12 months without restimulation with AuTu. In contrast, the parent cells required frequent AuTu restimulation and stopped growing by 20 weeks. In the parental T cell line, containing 90% of CD8+ and 10% CD4+ cells at week 10-12 of culture, the ratio of CD4+/ CD8+ cells shifted to 1 by week 20. The immortalized T cells were CD3+CD4+(100%) and the expression of this phenotype remained stable in culture. These immortalized T cells mediated AuTu cytotoxicity and retained the same specificity of lysis as the parental line. They did not kill K562 or Daudi targets. However, AuTu cytotoxicity mediated by the immortalized CD4+ cells was not inhibited by mAbs specific for CD3, CD4 or MHC-class II molecules. This cytotoxicity tended to reach a plateau at the 10: 1 effector-to-target cell ratio in 4 h 51Cr-release assays, as shown in Figure 2A . By comparing activities of CD4+ Fig.2 Cytotoxicity of immortalized CD4+T cells or parental CTL against AuTu. Cytotoxicity was measured in 4 h 51Cr-release assays using PCI-50 monolayers labeled in situ with 51Cr (A). In (B), DNA fragmentation and lysis of PCI-50 cells induced by immortalized T cells.
[3H]-thymidine or-51Cr-labeled PCI-50 cells were co-cultured with immortalized T cells at the E: T ratio of 40: 1 for different times before harvest. For DNA fragmentation assay.38) PCI-50 cells were frozen and thawed three times and harvested with automated cell harvester. Activity of 3H incorporated in unfragmented DNA or of 51Cr released in culture medium wasmeasured in a beta-counter. DNA fragmentation was calculated as:
51 Cr-release assays were performed as described by us earlier. 39) Using an episomal expression vector pREP4 (Invitrogen Inc., San Diego, CA), we have recently transduced two SCCHN cell lines and the HR cell line with the human IL2 gene (a 528 by DNA fragment obtained from the plasmid PBCII/RSV/T by digestion with restriction enzymes Barn HI and HindIII), selected transduced tumor cells for hygromycin resistance and shown by immunostaining that they contain intracytoplasmic IL2 and by RT-PCR that mRNA for IL2 is present in the cells (Fig.3) . These transduced tumor cell lines secreted minimal levels of IL2, however, as determined by IL2-specific ELISA. Transductions with the DFG-IL2 retroviral supernatant are in progress, and IL2 production by transiently induced PCI-1 or PCI-50 cells (tested 48 h after transduction) was in the range of 1-2 ng/ml/106 cells/48 h, as compared to none for non-transduced cultures. We expect that these tumor cell transfectants will be able to form tumors in nude mice and to produce IL2 at the desired concentrations in vivo. This strategy has been successfully used by others in animal models of tumor growth. 28, 29) In In the SCCHN xenograft model established in our laboratory, and another xenograft model of gastric CA metastatic to liver,37) we have had an opportunity to deliver antitumor effector cells and IL2 to the tumor milieu, observe their movement in the tumor, determine functional properties of these cells and of the tumor cells in situ and, most important, relate these observations to tumor regression. This preclinical model has proven to be useful in obtaining a better understanding of the SCCHN biology and the type of effector-tumor cell interactions that might determine therapeutic efficacy of AIT. In the future, lessons learned from this model and other basic studies are likely to contribute to a more rational design of clinical trials in patients with HNC. Table 6 is a list of options that are now open or will shortly become opened to clinicians treating patients with HNC. The knowledge acquired through preclinical, basic studies can now begin to be applied to clinical studies in order to improve therapeutic efficacy for patients with HNC. Boring 
